Complete Data for DRREDDY

**Summary:** Total links: 16, Text length: 2,769 characters, Date: 2025-08-19 17:31:18

# Extracted Links

Link 1: https://scanx.trade/stock-market-news/orders-deals/dr-reddy-s-expands-u-s-generic-portfolio-with-carac-0-5-authorized-generic-launch/17108091#:~:text=Dr.%20Reddy's%20Laboratories%2C%20a%20global,drug%20portfolio%20in%20key%20markets

Link 2: https://scanx.trade/stock-market-news/orders-deals/dr-reddy-s-expands-u-s-generic-portfolio-with-carac-0-5-authorized-generic-launch/17108091#:~:text=Forge%20strategic%20partnerships%20to%20accelerate,ScanX%20News%20Orders%20&%20Deals%20Dr.

Link 3: https://scanx.trade/stock-market-news/orders-deals/dr-reddy-s-expands-u-s-generic-portfolio-with-carac-0-5-authorized-generic-launch/17108091#:~:text=Dr.%20Reddy's%20move%20to%20introduce,Carac%200.5%25%20Authorized%20Generic%20Launch

Link 4: https://hdfcsky.com/news/dr-reddys-q4-results-fy25-rises-by-22-percent

Link 5: https://www.drreddys.com/cms/cms/sites/default/files/2025-05/DRL\_Q4FY25%20Earnings%20Call%20Transcript\_9May2025.pdf

Link 6: https://www.goodreturns.in/news/dr-reddy-s-q4-results-2025-live-net-profit-jumps-22-revenue-up-20-announces-800-dividend-1-5-1428215.html#:~:text=Reddy's%20Q4%20Results%202025:%20Net,Dividend%2C%201:5%20Stock%20Split&text=Dr%20Reddy's%20Laboratories%2C%20one%20of,the%20same%20quarter%20last%20year.

Link 7: https://www.moneycontrol.com/news/business/earnings/dr-reddy-s-labs-q4-results-net-profit-rises-22-to-rs-1-594-crore-beats-estimate-13019214.html#:~:text=Dr.,complex%20generics%2C%20and%20oncology%20assets.

Link 8: https://www.moneycontrol.com/news/business/earnings/dr-reddys-to-launch-over-20-products-in-us-in-fy25-12717218.html#:~:text=Volume,profit%20at%20Rs%201%2C291%20crore.

Link 9: https://www.indiainfoline.com/news/business/dr-reddys-plans-20-us-product-launches-in-fy25#:~:text=Dr.,along%20with%20increased%20R&D%20spending.

Link 10: https://www.newindianexpress.com/business/2025/May/19/dr-reddys-labs-stock-in-focus-amid-fda-inspection-report-q4-results#:~:text=Regulatory%20Development,year%20to%20%E2%82%B91%2C594%20crore.

Link 11: https://nsearchives.nseindia.com/corporate/DRREDDY\_09052025180415\_SE\_intimation\_Reg30\_09052025.pdf

Link 12: https://www.business-standard.com/markets/capital-market-news/dr-reddys-labs-manufacturing-facility-gets-two-form-483-observations-from-us-fda-125052600201\_1.html#:~:text=from%20US%20FDA-,Dr%20Reddys%20Labs'%20manufacturing%20facility%20gets%20two,483%20observations%20from%20US%20FDA&text=Dr%20Reddys%20Laboratories%20said%20that,Form%20483%20with%202%20observations.

Link 13: https://timesofindia.indiatimes.com/business/india-business/dr-reddys-receives-two-usfda-observations-for-new-york-api-facility/articleshow/121233940.cms#:~:text=Apple%20iPhone%20Production-,Dr%20Reddy's%20receives%20two%20USFDA%20observations%20for%20New%20York%20API,management%20to%20prompt%20corrective%20action.

Link 14: https://money.rediff.com/news/market/dr-reddy-s-gets-usfda-observations-for-telangana-api-plant/27455320250525#:~:text=The%20observations%20were%20issued%20in,of%20rediff.com%20India%20Limited.

Link 15: https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-gets-2-observations-from-usfda-for-telangana-api-plant/articleshow/121391800.cms#:~:text=Dr.,concerns%20within%20the%20given%20timeframe.&text=Dr%20Reddy's%20Laboratories%20has%20received,FD&C)%20Act%20and%20related%20Acts.

Link 16: https://www.livemint.com/market/market-stats/dr-reddys-laboratories-q4-results-s0003058#:~:text=DRREDDY%20Q4%20Results:%20Check%20out%20Dr%20Reddys,and%20highlights.%20%7C%20DRREDDY%20Q4%20Results%202025.

# Extracted Text Content

Q4 FY25 Results:On May 9th, Dr. Reddy's announced strong results for Q4 FY25, reporting a 22% increase in consolidated net profit year-on-year (YoY) to ₹1,594 crore, surpassing market expectations. Revenue also rose significantly by 20% YoY to ₹8,506 crore. This growth was attributed to factors like a strong performance in global generics, particularly in key markets such as Europe and India, and contributions from the acquired Nicotine Replacement Therapy (NRT) business.  
  
Dividend Declaration and Stock Split:Along with the results, Dr. Reddy's declared an 800% dividend (₹8 per share with a face value of ₹1) for shareholders. This follows a 1:5 stock split in October 2024.  
  
USFDA Observations:Dr. Reddy's received Form 483 with two observations from the USFDA following inspections at two of its API (Active Pharmaceutical Ingredient) manufacturing facilities:  
  
Middleburgh, New York:Inspection conducted from May 12-16, 2025, resulted in two observations, which the company pledged to address within the stipulated timeline.  
  
Miryalaguda, Telangana:Inspection conducted from May 19-24, 2025, also resulted in two observations, which the company will address promptly.  
  
Vietnam Expansion:Dr. Reddy's Laboratories SA, Switzerland, a wholly-owned subsidiary, incorporated a new wholly-owned subsidiary in Vietnam named "Dr. Reddy's Laboratories (Vietnam) Company Limited" on May 9, 2025. This aims to expand the company's presence and operations in the Vietnamese market, focusing on healthcare and pharmaceutical products, medical devices, and marketing/consulting services.  
  
US Generics Portfolio:Dr. Reddy's expanded its US generic portfolio by launching an authorized generic version of Carac 0.5% (fluorouracil cream), a medication used to treat actinic keratosis, in partnership with Extrovis AG.  
  
FY25 Product Launches:The company announced plans to launch over 20 new products in the US market during FY25, building on the 21 new molecules launched in FY24.  
  
R&D Investment:Dr. Reddy's emphasized its ongoing commitment to research and development, with full-year R&D investment for FY25 reaching ₹2,738 crores ($320 million), a 20% increase YoY, focused on developing a differentiated pipeline including biosimilars, complex generics, and novel oncology assets.  
  
USFDA Observations:Dr. Reddy's received Form 483 with two observations from the USFDA following inspections at two of its API (Active Pharmaceutical Ingredient) manufacturing facilities:Middleburgh, New York:Inspection conducted from May 12-16, 2025, resulted in two observations, which the company pledged to address within the stipulated timeline.Miryalaguda, Telangana:Inspection conducted from May 19-24, 2025, also resulted in two observations, which the company will address promptly.